EP0061274A1 - Procédé et intermédiaires pour la production de 6-(2-amino-2-phénylacétamido)pénicillanates de 1,1-dioxo penicillanoyloxyméthyle - Google Patents

Procédé et intermédiaires pour la production de 6-(2-amino-2-phénylacétamido)pénicillanates de 1,1-dioxo penicillanoyloxyméthyle Download PDF

Info

Publication number
EP0061274A1
EP0061274A1 EP82301296A EP82301296A EP0061274A1 EP 0061274 A1 EP0061274 A1 EP 0061274A1 EP 82301296 A EP82301296 A EP 82301296A EP 82301296 A EP82301296 A EP 82301296A EP 0061274 A1 EP0061274 A1 EP 0061274A1
Authority
EP
European Patent Office
Prior art keywords
formula
acid
compound
mixture
dioxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP82301296A
Other languages
German (de)
English (en)
Other versions
EP0061274B1 (fr
Inventor
Vytautas John Jasys
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Pfizer Inc
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL, Pfizer Inc filed Critical Pfizer Corp Belgium
Priority to AT82301296T priority Critical patent/ATE16595T1/de
Publication of EP0061274A1 publication Critical patent/EP0061274A1/fr
Application granted granted Critical
Publication of EP0061274B1 publication Critical patent/EP0061274B1/fr
Priority to KE370587A priority patent/KE3705A/xx
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/28—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with modified 2-carboxyl group
    • C07D499/32—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the invention relates to novel compounds of formula (I), defined herein, a process for their use in production of 1,1-dioxopenicillanoyloxymethyl 6-(2-amino-2-phenylacetamido)penicillanate antibiotics of formula (II), certain halomethyl (and related) esters of 6-halo (or 6,6-dihalo)penicillanic acid and the corresponding sulfoxides and sulfones useful in .preparing compounds of formula (I).
  • U.S. 4,244,951 discloses novel antibacterial agents of formula (VIII) in which penicillanic acid 1,1-dioxide is linked to known penicillin antibiotics via a methylenedioxo group, i.e., where R b is the acyl group of a natural or semisynthetic penicillin.
  • R b is the acyl group of a natural or semisynthetic penicillin.
  • Especially preferred values for R b include 2-amino-2-phenylacetyl and 2-amino-2-(p-hydroxyphenyl)-acetyl.
  • the compounds (VIII) are prepared, for example, by reacting a carboxylate salt of the penicillin such as the sodium, potassium or tertiary amine salt with a halomethyl ester (or related ester) of-penicillanic acid 1,1-dioxide.
  • the intermediate halomethyl esters are prepared by esterification of penicillanic acid 1,1-dioxide.
  • Belgian Patent 882,028, granted September 9, 1980 discloses a process for preparing penicillanic acid 1,1-dioxide and its readily hydrolyzable in vivo esters by oxidation of 6-halopenicillanate or a 6,6-dihalopenicillanate to the corresponding 1,1-dioxide, then dehalogenation to provide the desired penicillanate 1,1-dioxide.
  • U.S. 3,293,242 discloses 6-(2-azido-2-phenylacet- amido)penicillanic acid and salts thereof.
  • the present invention relates to compounds of the formula wherein R 1 is H or OH; Y and Z are each Cl, Br or I, or Y is H and Z is Cl, Br or I; and Q is N 3 or NHCO 2 CH 2 C 6 H 4 R 4 where R is H, Cl, Br, NO 2 , CH 3 or OCH 3 useful as intermediates for the production of valuable antibiotics of the formula
  • the particularly preferred value for Q is N 3 .
  • Particularly preferred values for Y and Z are Y is H and Z is Br or Cl, or Y and Z are each Cl or Br; especially Y is H, Z is Br or Y and Z are each Br.
  • Most particularly preferred such compounds are those wherein Q is N 3 , R is H or OH, Y and Z are each Br.
  • the invention also provides a novel process for production of the antibiotics of formula (II) which is characterized by contacting a compound of formula (I) with hydrogen in the presence of a noble metal catalyst and a reaction inert solvent.
  • the invention process has advantages over the prior art in that simultaneously the halogen atoms Y and Z are subjected to hydrogenolysis and the group Q is reduced (when Q is N 3 ) or subjected to hydrogenolysis (when Q is NHC0 2 CH 2 C 6 H 4 R 4 ) to produce the antibiotics of formula (II) in a single step.
  • a particularly preferred noble metal catalyst for this process is palladium.
  • the invention further provides novel intermediates which are useful in preparation of compounds of formula (I). These intermediates are of the formula where Y and Z are as defined above for compound ( I ), n is zero, 1 or'2; and X is Cl, Br, I or OSO 2 R 2 where R 2 is alkyl having from one to six carbon atoms or C 6 H 4 R 3 and R 3 is Cl, Br, I, N0 2 or alkyl or alkoxy, where each of the latter two groups have from one to three carbon atoms.
  • Particularly preferred intermediates of formula (IV) are those where:
  • This invention relates to derivatives of penicillanic acid which is represented by the following structural formula:
  • broken line attachment (''') of a substituent to the bicyclic nucleus indicates that the subsitutent is below the plane of the nucleus. Such a substituent is said to be in the alpha-configuration.
  • broad line attachment ( ) of a substitutent to the bicyclic nucleus indicates that the substituent is above the plane of the nucleus. This latter configuration is referred to as the beta-configuration.
  • a solid line attachment ( ⁇ ) of a substituent to the bicyclic nucleus indicates that the substituent'can be in either the alpha-configuration or the beta-configuration.
  • one of A and B is -CH 2 X 1 and the other is M 1 , where X 1 is a good leaving group, e.g., Cl, Br, I, CH 3 SO 2 O or toluenesulfonyloxy; and M is a carboxylate salt forming cation, e.g., sodium, potassium, triethylammonium or tetrabutylammonium ion;' and Q 1 is a conventional amino protecting group, e.g., benzyloxycarbonyl.
  • the initial product obtained is the amino-protected derivative of (II) which affords the desired antibiotic compound upon removal of protecting group Q by standard methods known in the art.
  • the ester (IX), where A is CH 2 X 1 is obtained from the acid by certain esterification techniques.
  • Flow Chart A outlines a preferred method for production of the invention compounds of formula (I) and their conversion to antibiotic compounds of formula (II) by simultaneous hydrogenolysis of halogen groups Y and Z and reduction of the azido or NHCO 2 CH 2 C 6 H 4 R 4 group to NH 2 by reaction of compound (I) with hydrogen in the presence of a catalyst.
  • the starting halopenicillanic acids of formula (III) where M is hydrogen are prepared e.g., from 6-aminopenicillanic acid or the corresponding sulfoxide or . sulfone by reaction with nitrous acid and treatment of the resulting 6-diazo compound with a halogen or hydrohalide of formula Y-Z, where Y and Z are as defined above, by methods known in the art. See, e.g., Clayton et al., Journal of Chemical Society (London) (C), 2123 (1969).
  • the carboxylic acid (III) is converted to a salt wherein M is a cation.
  • M is a cation.
  • a variety of cations can be used to form the carboxylate salt in the compound of formula (III), but salts which are commonly employed include:
  • the salt of formula (III) is reacted with a compound of the formula X 2 CH 2 X, wherein X is as defined above and X 2 is X or a better leaving group than X, e.g., when X is Cl, X 2 may be Cl, B r, I, OSO 2 Cl, OS0 2 CH 3 or p-CH 3 C 6 H 4 SO 2 O. Particularly preferred values for X 2 are I and OSO 2 Cl.
  • the reaction between X 2 CH 2 X and the salt of formula (III) is usually carried out by contacting approximately equimolar 'amounts of the reactants in a polar, organic solvent, at a temperature in the range of from about -10 to 80°C. and preferably from about 0 to 60°C.
  • the reaction is ordinarily complete in from a few hours to a few days.
  • the desired ester of formula (IV) is isolated by methods well known in the art. For example, by evaporation of solvent and purification of the crude product, if desired, e.g.,' by column chromatography.
  • Suitable polar solvents which can be employed in this reaction are dimethylformamide, N-methylpyrrolidone, dimethylsulfoxide, ethyl acetate, dichloromethane, acetone and hexamethylphosphoric triamide; alternately, an excess of the reagent X 2 CH 2 X e.g., ICH 2 Cl, can serve as solvent.
  • the compounds of formula (IV) where n is zero or one are oxidized to the corresponding sulfone of formula (V).
  • oxidizing agents any of the oxidizing agents known in the art for oxidation of sulfides to sulfones may be employed in this step, preferred oxidizing agents are sodium permanganate, potassium permanganate, calcium permanganate, hydrogen peroxide in the presence of certain transiticn metal catalysts, peractic acid or m-chloroperbenzoic acid.
  • the oxidation is carried out in the presence of a reaction inert solvent., preferably at a temperature of from about -30 to 60°C.
  • oxidizing agents are hydrogen peroxide in the presence of certain transition metal catalysts,.potassium permanganate and m-chloroperbenzoic acid. Especially preferred are potassium permanganate and m-chloroperbenzoic acid.
  • reaction is usually carried out by treating the compound of the formula (IV) with from about two to about ten molar equivalents, and preferably from about two to about four molar equivalents, of the permanagnate in an appropriate, reaction-inert solvent system.
  • reaction-inert solvent system is one that does not adversely interact with either the starting materials or the product, and water is commonly used. If desired, a co-solvent which is miscible with water but will not interact with the permanganate such as e.g., tetrahydrofuran or acetone can be added.
  • the reaction can be carried out at a temperature in the range from about -30° to about 60°C., and it is preferably carried out at about 10 to about 30°C. At about room temperature the reaction is normally substantially complete within a short period, e.g. within two hours.
  • the reaction can be-carried out under neutral, basic or acid conditions, it is preferable to operate at a pH in the range from about 4 to about 9.
  • the product is recovered by conventional technqiues. Any excess permanganate is usually decomposed using sodium bisulfite, and then if the product is out of solvent, it is recovered by filtration. It is separated from manganese dioxide by extracting it into an organic solvent and removing the solvent by evaporation. Alternatively, if the product is not out of solution at the end of the reaction, it is isolated by the usual procedure of solvent extraction.
  • the reaction is usually carried out by treating the compound of the formula (V) with from about 2 to about 6 molar equivalents, and preferably about 2.2 molar equivalents of the oxidant in a reaction-inert organic solvent.
  • a peroxycarboxylic acid e.g. m-chloroperbenzoic acid
  • the reaction is usually carried out by treating the compound of the formula (V) with from about 2 to about 6 molar equivalents, and preferably about 2.2 molar equivalents of the oxidant in a reaction-inert organic solvent.
  • a peroxycarboxylic acid e.g. m-chloroperbenzoic acid
  • Preferred reaction-inert solvents are chlorinated hydrocarbons, such as dichloromethane, chloroform and 1,2-dichloroethane; ethers, such as diethyl ether, tetrahydrofuran and 1,2-dimethoxyethane; and ethyl acetate.
  • the reaction is normally carried out at a temperature of from about -30 to about 50°C., and preferably from about -15 to about 30°C. At about 0°C., reaction times of about 4 to about 16 hours are commonly used.
  • the product of formula (V) is isolated by standard methods, e.g., decomposition of excess oxidant by addition of sodium bisulfite, partitioning the reaction mixture between water and water-immiscible solvent and evaporation of solvent from the washed extract.
  • the crude product can be purified, e.g., by chromatography on silica gel.
  • transition metal catalysts When hydrogen peroxide in the presence of certain transition metal catalysts is employed to oxidize a sulfide or sulfoxide such as the compounds of formula ( IV ) wherein n is zero or 1 to the corresponding sulfone of formula (V), preferred transition metal catalysts are inorganic compounds of tungsten, molybdenum or zirconium in which the metals are in their highest oxidation state. Examples of such compounds are tungstic acid, sodium tungstate, zirconium tetrachloride, molybdic acid and potassium molybdate.
  • the transition metal catalysts can be carried out over a pH range of about 3 to 9, however a pH of from about 4 to 7 is preferred.
  • the compound to be oxidized is a sulfide, such as that of formula (IV) where n is zero, at least two moles of hydrogen peroxide per mole of said sulfide is required to provide the corresponding sulfone.
  • Preferred reaction inert solvents for the oxidation with hydrogen peroxide/ transition metal catalyst / include the lower alkanols such as methanol, ethanol and isopropanol; ethylene glycol, ethyl acetate, 1,2-dimethoxyethane, water and mixtures thereof.
  • a preferred temperature is in the range from about 20 to 60°C., at which temperature the oxidation is ordinarily complete in from about two hours to two days, e.g., overnight.
  • the desired product is then isolated and can be purified, if desired, by methods described above and in the Examples.
  • the reaction of the intermediates (V) with the 6-(2-Q-substituted-2-phenylacetamido)penicillanate salts of formula (VI) where M is as previously defined for compound (III), to provide the invention compounds of formula (I) is usually carried out by contacting the reactants in a polar, organic solvent at a temperature in the range from about 0°C ' . to . about 80°C. and preferably from 25° to 50°C.
  • the compounds of formula (V) and (VI) are usually contacted in substantially equimolar proportions, but an excess . of either reagent, for example up to a ten-fold . excess, can be used.
  • solvents can be used, but it is usually advantageous to use a relatively polar solvent, since this has the effect of speeding up the reaction.
  • Typical solvents which can be used include N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, dimethylsulfoxide, ethyl acetate, dichloromethane, acetone and hexamethylphosphoric triamide.
  • the reaction time varies according to a number of factors, but at about 25°C. reaction times of several hours, e.g. 12 to 24 hours, are commonly used.
  • the compound of formula (I) is isolated in conventional fashion. When a water-miscible solvent is used, it is usually sufficient simply to dilute the reaction medium with an excess of water. The product is then extracted into a water immiscible solvent such as ethyl acetate, and then the product is recovered by solvent evaporation. When a water immiscible solvent is used, it is usually sufficient to wash the solvent with water, and then recover the product by solvent evaporation.
  • the compound of formula (I) can be purified by well-known methods, such as recrystallization or chromatography, but due regard must be given to the lability of the beta-lactam ring system.
  • the sulfide, (III, n 0),. wherein M, Y and Z are as previously defined, is reacted with a compound of the formula X 2 CH 2 Cl where X 2 is as defined above, e.g., ICH 2 Cl, employing methods and conditions defined previously for the preferred method employing X 2 CH 2 X.
  • suitable solvents for this reaction are dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, methanol, ethanol, ethyl acetate, acetone and methylethyl ketone.
  • a preferred solvent is acetone.
  • reaction can be carried out successfully over a wide range of temperature, a temperature in the range of about 0 to 50°C., and especially 20 to 40°C. is preferred. Within the latter range of temperature the reaction is ordinarily complete in from about 1 to 20 hours.
  • At least two moles of hydrogen peroxide per mole of said sulfide is required to provide the corresponding sulfone.
  • An alternate method for obtaining the valuable intermediates of formula (I) involves reaction of a compound of formula (XI) with a compound of formula (XII) as illustrated below wherein R 1 , M, Q, X , Y and Z are as previously defined, employing the same procedure and conditions described above for the coupling reaction with compounds of formulae'(V) and (VI).
  • the compounds of formula (I) are useful intermediates for production of the valuable antibiotic compounds of formula (II), disclosed in U.S.. 4,244,951.
  • a particularly convenient and preferred method is the simultaneous hydrogenolysis of halogen groups Y and Z as defined above and reduction of the azido or benzyloxycarbonylamino group Q, as defined above, to NH 2 by means of hydrogen in the presence of a noble metal catalyst.
  • a particularly convenient method for carrying out this simultaneous hydrogenolysis and reduction is to stir or shake a solution of a compound of the formula (I) under an atmosphere of hydrogen, or hydrogen mixed with an inert diluent such as nitrogen or argon, in the presence of a noble metal hydrogenation catalyst, and a reaction inert solvent.
  • Suitable solvents for this hydrogenation reaction are those which substantially dissolve the starting compound of the formula (I) but which do not themselves suffer hydrogenation or.hydrogenolysis.
  • solvents include lower alkanols such as methanol, ethanol and isopropanol; ethers such as diethyl ether, tetrahydrofuran, dioxan and 1,2-dimethoxyethane; low molecular weight esters such as ethyl acetate and butyl acetate; tertiary amides such as N,N-dimethylformamide, N,N-dimethylacetamide and N-methylpyrrolidone: methylene chloride and mixtures thereof.
  • an acid binding agent to bind one or both molar equivalents of hydrogen halide formed.
  • suitable acid binding agents include sodium bicarbonate, calcium carbonate, trisodium phosphate, potassium citrate and tertiary amines such as triethylamine, N,N-dimethylaniline, N-methylmorpholine, N-methylpiperidine, N,N'-dimethylpiperazine and the like.
  • Introduction of the hydrogen gas into the reaction medium is usually accomplished by carrying out the reaction in a sealed vessel, containing the compound of formula (I), the solvent, the catalyst and the hydrogen.
  • the pressure inside the reaction vessel can vary from about 1 to about 100 kg./cm..
  • the preferred pressure range when the atmosphere inside the reaction vessel is substantially pure hydrogen, is from about 2 to about 5 kg./cm. 2 .
  • the reaction with.hydrogen is generally run at a temperature of from about 0° to about 60°C., and preferably from about 25° to about 50°C. Utilizing the preferred temperature and pressure values, hydrogenolysis of halogens and reduction of the group Q generally takes place in a few hours, e.g., from about 2 hours to about 20 hours.
  • the preferred noble metal catalysts used in this hydrogenation reaction are the type of agents known in the art for this kind of transformation, for example, nickel, palladium, platinum and rhodium. Palladium is particularly preferred.
  • the catalyst is usually present in an amount from about 0.1 to about 25 weight-percent, and preferably from about 1 to about 10 weight-percent, based on the compound of formula (I). It is often convenient to suspend the catalyst on an inert support; one particularly convenient catalyst is palladium suspended on an inert support such as carbon. Another convenient catalyst is palladium-on-calcium carbonate in which' the calcium carbonate serves as a support for the noble metal, and as acid binding agent.
  • the desired antibiotic of formula (II) is then isolated by standard methods, e.g., the catalyst is removed by filtration, the solvent evaporated and the product purified, if desired, by well known methods such as crystallization or by chromatography.
  • the product of formula (II) can be isolated in the form of a pharmaceutically acceptable acid addition salt, for example by treating filtrate obtained upon removal of catalyst or a solution of the isolated free base with an equivalent amount of a pharmaceutically acceptable acid and removal of solvent, e.g. by filtration or evaporation.
  • pharmaceutically acceptable acids which may be employed include hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, maleic, fumaric, succinic, lactic, tartaric, citric, gluconic, saccharic and E - toluenesulfonic acids.
  • hydrochloride, hydrobromide, hydroiodide salt or mixtures thereof of compounds of formula (II) is obtained directly from the hydrogenation mixture if one employs only one molar equivalent of acid binding agent for the starting materials of formula (I) wherein each of Y and Z are Cl, Br or I, or no acid binding agent is employed for starting materials of formula (I) wherein Y is H and Z is Cl, Br or I.
  • the compounds of formula (II) and (VII1) possess in vivo antibacterial activity in mammals, and this activity can be demonstrated by standard techniques for penicillin compounds.
  • the compound of formula (II) is administered to mice in which acute infections have been established by intraperitoneal inoculation with a standardized culture of a pathogenic bacterium. Infection severity is standardized such that the mice receive one to ten times the LD100 (LD 100 : the minimum inoculation required to consistently kill 100 percent of control mice).
  • LD 100 the minimum inoculation required to consistently kill 100 percent of control mice.
  • the activity of the compound is assessed by counting the number of survivors which have been challenged by the bacterium and also have received the compound of formula (II).
  • the compounds of formula (II) can be administered by both the oral (p.o.) and subcutaneous (s.c.) route.
  • the in vivo activity of the antibacterial compounds (II) and (VIII) make them suitable for the control of bacterial infections in mammals, including man, by both the oral and parenteral modes of administration.
  • the compounds are useful in the control of infections caused by susceptible bacteria in human subjects. In general, it is the substituent R b which determines whether a given bacterium will be susceptible to a given compound of formula (VIII).
  • R b which determines whether a given bacterium will be susceptible to a given compound of formula (VIII).
  • a compound of formula (VIII) breaks down to the corresponding compound of formula (VII) (or salt thereof) and penicillanic acid 1,1-dioxide (XIII) after administration to a mammalian subject by either the oral or parenteral route.
  • Penicillanic acid 1,1-dioxide then functions as a beta-lactamase inhibitor, and it increases the' antibacterial effectiveness of the compound of formula (VII) (or salt thereof).
  • R b is D -2-amino-2-phenylacetyl or D-2-amino-2-[4-hydroxyphenyl]-acetyl the compounds are useful in the control of infections caused by susceptible strains of Escherichia coli and Staphylococcus aureus.
  • the in vivo test described earlier can be used.
  • the minimum inhibitory concentration (MIC) of a 1:1 mixture of the compound of formula (VII) (or its salt) and the compound of formula (XIII) (or its salt) can be measured.
  • the MIC's can be measured by the procedure recommended by the International Collaborative Study on Antibiotic Sensitivity Testing (Ericcson and Sherris, Acta. Pathologica et Micro- biologia Scandinav, Supp.
  • B H I brain heart infusion
  • Overnight growth tubes are diluted 100 fold for use as the standard inoculum (20,000-10,000 cells in approximately 0.002 ml. are placed on .the agar surface; 20 ml. of BHI agar/dish). Twelve 2 fold dilutions of the test compound are employed, with initial concentration of the test drug being 200 mcg./ml. Single colonies are disregarded when reading plates after 18 hrs. at 37°C.
  • the susceptibility (MIC) of the test organism is accepted as the lowest concentration of compound capable of producing complete inhibition of growth as judged by the naked eye.
  • an antibacterial compound of formula (II), or a salt thereof in a mammal, particularly man, the compound can be administered alone, or it can be mixed with other antibiotic substances and/or pharmaceutically-acceptable carriers or diluents.
  • Said carrier or diluent is chosen on the basis of the intended mode of administration.
  • the antibacterial compound (II) can be used in the form of tablets, capsules, lozenges, troches, powders, syrups, elixirs, aqueous solutions and suspensions, and the like, in accordance with standard pharmaceutical practice.
  • the proportional ratio of active ingredient to carrier will naturally depend on the chemical nature, solubility and stability of the active ingredient, as well as the dosage contemplated.
  • carriers which are commonly used include lactose, sodium citrate and salts of phosphoric acid.
  • Various disintegrants such as starch, and lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc, are commonly used in tablets.
  • useful diluents are lactose and high molecular weight polyethylene glycols, e.g. polyethylene glycols having molecular weights of from 2000 to 4000.
  • the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents can be added.
  • sterile solutions of the active ingredient are ' usually prepared, and the pH of the solutions are suitably adjusted and buffered.
  • the total concentration of solutes should be controlled to render the preparation isotonic.
  • the antibacterial compounds of formula (II) and pharmaceutically acceptable salts thereof are of use in human subjects and the daily dosages to be used will not differ significantly from other, clinically- used, penicillin antibiotics.
  • the prescribing physician will ultimately determine the appropriate dose for a given human subject, and this can be expected to vary according to the age, weight, and response of the individual patient as well as the nature and the severity of the patient's symptoms.
  • the compounds (II) will normally be used orally at dosages in the range from about 20 to about 100 mg. per kilogram of body weight per day, and parenterally at dosages from about 10 to about 100 mg. per kilogram of body weight per day, usually in divided doses. In some instances it may be necessary to use doses outside these ranges.
  • IR Infrared
  • KBr discs potassium bromide discs
  • diagnostic absorption bands are reported in wave numbers (cm -1 ).
  • Nuclear magnetic resonance spectra were measured at 60 MHz for solutions in deuterated chloroform (CDC1 3 ), D20 , CD3S OC D3 , or deuterated acetone (CD 3 COCD 3 ), and peak positions are reported in parts per million downfield from tetramethylsilane.
  • NMR nuclear magnetic resonance spectra
  • peak shapes are used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, double doublet.
  • 6,6-Dibromopenicillanic acid (8.0 g., 22 mmole) was stirred with 75 ml. methylene chloride, 35 ml. water was added. To this was added tetrabutylammonium hydroxide to adjust to pH 8. The organic layer was separated, the aqueous phase extracted with 30 ml. methylene chloride. The combined organic layers were evaporated to dryness in vacuo to provide'the tetrabutylammonium salt of 6,6-dibromopenicillanic acid, 14.2 g., as a light brown oil. To this was added 40 ml. of chloroiodomethane, and the resulting 'mixture stirred under nitrogen for three hours at room temperature.
  • iodomethyl 6,6-dibromopenicillanate methylsulfonyloxymethyl 6,6-dibromopenicillanate, isobutylsulfonyloxymethyl 6,6-dibromopenicillanate, n-hexylsulfonyloxymethyl 6,6-dibromopenicillanate, benzenesulfonyloxymethyl 6,6-dibromopenicillanate, and R 2 -C 6 H 4 -sulfonyloxymethyl 6,6-dibromopeni- cillanates where R 2 is as defined above for the di(substituted phenylsulfonyloxy)methane reagent.
  • bromomethyl 6,6-dibromopenicillanate bromomethyl 6,6-dichloropenicillanate, chloromethyl 6,6-dichloropenicillanate, chloromethyl 6-bromo-6-chloropenicillanate, chloromethyl 6-chloro-6-iodopenicillanate, chloromethyl 6-bromo-6-iodopenicillanate or bromomethyl 6-bromo-6-iodopenicillanate in place of chloromethyl 6,6-dibromopenicillanate in the above procedure provides the corresponding iodomethyl ester, in each case.
  • Example 1B Employing the compounds provided in Example 1B as starting materials in the.procedures of Example 2 through 4 provides the corresponding compound of the formula below where Y, Z and X are as defined in Example 1B.
  • the same product is obtained by employing chloromethyl 6,6-dibromopenicillanic acid in the above procedure and oxidizing the resulting sulfide, chloromethyl 6-beta-bromopenicillanate, to the sulfone by the procedures of Example 2, 2A, 3 or 4.
  • An oxidizing solution was prepared from 185 mg. of potassium permanganate, 0.063 ml. of 85% phosphoric acid and 5 ml. of water. This oxidizing solution was added dropwise to a solution of 150 mg. of sodium 6-beta-chloropenicillanate in 5 ml. of water at 0-5°C., until the purple color of the potassium permanganate persisted. Approximately half of the oxidizing solution was required. At this point, the potassium permanganate color was discharged by the addition of solid sodium bisulfite, and then the reaction mixture was filtered. Ethyl acetate was added to the filtrate and the pH was adjusted to
  • 6-alpha-Bromopenicillanic acid 1,1-dioxide is esterified by the procedure of Example 1 to provide the title compound.
  • chloroiodomethane used therein is replaced by an equimolar amount of bromoiodomethane, diiodomethane, di(methyl- sulfonyloxy)methane, di(isopropylsulfonyloxy)methane, di(isovalerylsulfonyloxy)methane or a compound of the formula (R 2 C 6 H 4 SO 2 O) 2 CH 2 where R 2 is H, 3-Cl, 4-Br, 4-NO 2 , 4-CH 3 , 3-n-C 3 H 7 , 4-CH 3 O, 4-C 2 H 5 O or 3-(CH 3 ) 2 CH 2 to provide, respectively:
  • the title compound is prepared by oxidation of 6-alpha-chloropenicillanic acid by oxidation with one equivalent of 3-chloroperbenzoic acid in tetrahydrofuran at 0-25°C. for about one hour, according to the procedure of Harrison et al., Jour. Chem. Soc. (London), Perkin I, 1772 (1976).
  • the resulting 6-alpha-chloropenicillanic acid 1- oxide is then esterified by the procedure of Example 1 to provide the desired chloromethyl ester.
  • the same compound is obtained by reaction of 0.1 mole chloromethyl 6-alpha-chloropenicillanate in 150 ml. isopropanol containing 0.8 ml. of 0.5M sodium tungstate (Na 2 W0 4 ) or an equivalent amount of potassium molybdate (R 2 MoO 4 ) with 0.1 mole of hydrogen peroxide (30%).
  • the peroxide is added slowly to the other reagents at 60°C., after which the mixture is allowed to cool while stirring overnight.
  • the product is isolated as described above.
  • the title compound is obtained by oxidation of the same starting material in methanol or ethanol containing a catalytic amount of sodium tungstate and addition of 2 molar.equivalents of hydrogen peroxide at temperatures of from 20 to 60°C.
  • penicillanate 1-oxides provided in Example 14 are converted to 1,1-dioxides by the above procedure employing one half the amount of m-chloroperbenzoic acid, or by employing an equimolar amount of peracetic acid.
  • the tetrabutylammonium salt was prepared as follows: One gram of sodium D-2-azido-2-phenylacetamido penicillanate, 50 ml. ethyl acetate and 25 ml. water, were combined and adjusted to pH 2.0 (2N HC1). The organic layer was separated, washed with brine (10 ml.) and the solvent evaporated in vacuo. The residual foam was dissolved in 30 ml. methylene.chloride, 15 ml. water was added and 40% tetrabutylammonium hydroxide solution was added until the aqueous phase reached pH 8.0.
  • the title compound is obtained by employing tetrabutylammonium 6-(D-2-benzyloxycarbonylamino-2-phenylacetamido)penicillanate in place of the corresponding azidocillin salt in the procedure of Example 10.
  • 6-Chloro-6-bromopenicillanic acid is prepared from 6-aminopenicillanic acid via diazotization followed by reaction with bromine chloride, according to the procedure of Preparation D.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Cephalosporin Compounds (AREA)
EP82301296A 1981-03-23 1982-03-15 Procédé et intermédiaires pour la production de 6-(2-amino-2-phénylacétamido)pénicillanates de 1,1-dioxo penicillanoyloxyméthyle Expired EP0061274B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AT82301296T ATE16595T1 (de) 1981-03-23 1982-03-15 Verfahren und zwischenprodukte zur herstellung von 1,1-dioxo-penicillanoyloxymethyl-6-(2-amino-2-p enylacetamido)penicillansaeureestern.
KE370587A KE3705A (en) 1981-03-23 1987-03-20 Process and intermediates for production of 1,1-dioxopenicillanoyloxymethyl 6-(2-amino-2-phenylacetamido)penicillanates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24645681A 1981-03-23 1981-03-23
US246456 1994-05-20

Publications (2)

Publication Number Publication Date
EP0061274A1 true EP0061274A1 (fr) 1982-09-29
EP0061274B1 EP0061274B1 (fr) 1985-11-21

Family

ID=22930766

Family Applications (1)

Application Number Title Priority Date Filing Date
EP82301296A Expired EP0061274B1 (fr) 1981-03-23 1982-03-15 Procédé et intermédiaires pour la production de 6-(2-amino-2-phénylacétamido)pénicillanates de 1,1-dioxo penicillanoyloxyméthyle

Country Status (32)

Country Link
EP (1) EP0061274B1 (fr)
JP (3) JPS57169493A (fr)
KR (1) KR860001368B1 (fr)
AU (1) AU531892B2 (fr)
BG (2) BG38939A3 (fr)
CA (1) CA1213581A (fr)
CS (1) CS227345B2 (fr)
DD (1) DD202163A5 (fr)
DE (1) DE3267505D1 (fr)
DK (3) DK162392C (fr)
EG (1) EG15803A (fr)
ES (2) ES510655A0 (fr)
FI (1) FI74284C (fr)
GB (1) GB2095250A (fr)
GR (1) GR75935B (fr)
GT (1) GT198274393A (fr)
HK (1) HK52487A (fr)
HU (2) HU187667B (fr)
IE (1) IE52835B1 (fr)
IL (1) IL65308A (fr)
IN (1) IN159362B (fr)
MY (1) MY8700499A (fr)
NO (1) NO159658C (fr)
NZ (1) NZ200066A (fr)
PH (1) PH17602A (fr)
PL (3) PL134250B1 (fr)
PT (1) PT74621B (fr)
RO (2) RO84278B (fr)
SG (1) SG23387G (fr)
SU (2) SU1277898A3 (fr)
YU (2) YU42761B (fr)
ZA (1) ZA821899B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0084730A1 (fr) * 1982-01-22 1983-08-03 Beecham Group Plc Esters de dérivés de pénicilline avec des inhibiteurs de bêta-lactamase, leur préparation et leur application
EP0112087A1 (fr) * 1982-12-06 1984-06-27 Pfizer Inc. Procédé et intermédiaires pour la Sultamicilline et analogues
CN112724162A (zh) * 2020-12-28 2021-04-30 华南农业大学 一种阿莫西林-舒巴坦杂合分子的合成方法及应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8808701D0 (en) * 1988-04-13 1988-05-18 Erba Carlo Spa Beta-lactam derivatives
ES2039299B1 (es) * 1991-10-04 1994-05-16 Asturpharma S A Procedimiento de obtencion de esteres de acido 1,1-dioxopenicilanico y sus sales.
ES2100125B1 (es) * 1995-06-02 1998-04-01 Asturpharma S A Procedimiento de preparacion de esteres de metanodiol de acido dioxopenicilanico.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2044255A (en) * 1979-02-13 1980-10-15 Leo Pharm Prod Ltd Penicillin derivatives
GB2045755A (en) * 1979-03-05 1980-11-05 Pfizer Process and intermediates for penicillanic acid 1,1-dioxide and esters thereof
GB2059960A (en) * 1979-10-11 1981-04-29 Leo Pharm Prod Ltd Method for producing penicillanic acid derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA80796B (en) * 1979-02-13 1981-02-25 Leo Pharm Prod Ltd Chemical compounds
ZA80646B (en) * 1979-03-05 1981-02-25 Pfizer Process and intermediates for penicillanic acid,1,1-dioxide and esters thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2044255A (en) * 1979-02-13 1980-10-15 Leo Pharm Prod Ltd Penicillin derivatives
GB2045755A (en) * 1979-03-05 1980-11-05 Pfizer Process and intermediates for penicillanic acid 1,1-dioxide and esters thereof
GB2059960A (en) * 1979-10-11 1981-04-29 Leo Pharm Prod Ltd Method for producing penicillanic acid derivatives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0084730A1 (fr) * 1982-01-22 1983-08-03 Beecham Group Plc Esters de dérivés de pénicilline avec des inhibiteurs de bêta-lactamase, leur préparation et leur application
EP0112087A1 (fr) * 1982-12-06 1984-06-27 Pfizer Inc. Procédé et intermédiaires pour la Sultamicilline et analogues
CN112724162A (zh) * 2020-12-28 2021-04-30 华南农业大学 一种阿莫西林-舒巴坦杂合分子的合成方法及应用

Also Published As

Publication number Publication date
IN159362B (fr) 1987-05-09
DK121491A (da) 1991-06-21
DK167119B1 (da) 1993-08-30
JPS63146886A (ja) 1988-06-18
GT198274393A (es) 1983-09-08
KR830009113A (ko) 1983-12-17
NO820898L (no) 1982-09-24
PL240664A1 (en) 1983-09-12
JPH0331717B2 (fr) 1991-05-08
ES518970A0 (es) 1984-03-01
DK165746B (da) 1993-01-11
DK127182A (da) 1982-09-24
EG15803A (en) 1990-08-30
HU189917B (en) 1986-08-28
KR860001368B1 (ko) 1986-09-17
PT74621A (en) 1982-04-01
CA1213581A (fr) 1986-11-04
AU531892B2 (en) 1983-09-08
EP0061274B1 (fr) 1985-11-21
NO159658C (no) 1989-01-25
PL235578A1 (en) 1983-06-20
PT74621B (en) 1984-11-26
PL138851B1 (en) 1986-11-29
HUT34985A (en) 1985-05-28
DK21892D0 (da) 1992-02-20
RO87946B (ro) 1985-12-02
DK121491D0 (da) 1991-06-21
ES8403132A1 (es) 1984-03-01
DK165746C (da) 1993-06-07
BG37380A3 (en) 1985-05-15
SU1277898A3 (ru) 1986-12-15
FI820991L (fi) 1982-09-24
IL65308A (en) 1985-03-31
ES8305768A1 (es) 1983-04-16
NZ200066A (en) 1985-08-16
FI74284B (fi) 1987-09-30
ES510655A0 (es) 1983-04-16
PL240663A1 (en) 1983-09-12
JPS6345287A (ja) 1988-02-26
IE52835B1 (en) 1988-03-16
MY8700499A (en) 1987-12-31
PL139261B1 (en) 1987-01-31
RO84278A (fr) 1984-05-23
DE3267505D1 (en) 1986-01-02
BG38939A3 (en) 1986-03-14
YU61982A (en) 1985-03-20
AU8176482A (en) 1982-11-04
ZA821899B (en) 1983-01-26
YU42761B (en) 1988-12-31
CS227345B2 (en) 1984-04-16
SU1277897A3 (ru) 1986-12-15
SG23387G (en) 1987-07-10
DD202163A5 (de) 1983-08-31
DK21892A (da) 1992-02-20
YU43585B (en) 1989-08-31
GB2095250A (en) 1982-09-29
DK162392C (da) 1992-03-09
HK52487A (en) 1987-07-17
GR75935B (fr) 1984-08-02
RO84278B (ro) 1984-07-30
IL65308A0 (en) 1982-05-31
JPS57169493A (en) 1982-10-19
PL134250B1 (en) 1985-08-31
PH17602A (en) 1984-10-05
FI74284C (fi) 1988-01-11
DK162392B (da) 1991-10-21
HU187667B (en) 1986-02-28
IE820659L (en) 1982-09-23
YU181084A (en) 1987-06-30
NO159658B (no) 1988-10-17
RO87946A (fr) 1985-12-20

Similar Documents

Publication Publication Date Title
US4234579A (en) Penicillanic acid 1,1-dioxides as β-lactamase inhibitors
CA1178575A (fr) Bis-esters de methanediol avec des composes acetoniques d'amplicilline ou d'amoxicilline et l'acide dioxyde-1,1-penicillanique
US4419284A (en) Preparation of halomethyl esters (and related esters) of penicillanic acid 1,1-dioxide
US4093625A (en) 6-Sulfur analogs of penicillins and cephalosporins
EP0094227B1 (fr) Dérivés d'ampicilline et d'amoxycilline avec des inhibiteurs de bêta-laktamase
EP0061313B1 (fr) Bis-esters de 1,1-alcane-diols avec le 1,1-dioxyde de l'acide 6-béta-hydroxy-méthylpénicillanique et les antibiotiques bêta-lactames
EP0061274A1 (fr) Procédé et intermédiaires pour la production de 6-(2-amino-2-phénylacétamido)pénicillanates de 1,1-dioxo penicillanoyloxyméthyle
US4393001A (en) Intermediates for production of 1,1-dioxopenicillanoyloxymethyl 6-(2-amino-2-phenylacetamido)penicillanates
KR850001339B1 (ko) 페니실란산 1,1-디옥사이드 및 그의 에스테르의 제조방법
US4260598A (en) Method for increasing antibacterial effectiveness of a β-lactam antibiotic
EP0082666B1 (fr) Dérivés de bis-hydroxyméthylcarbonate comme agents antibactériens
US4364957A (en) Bis-esters of alkanediols as antibacterial agents
US4462934A (en) Bis-esters of dicarboxylic acids with amoxicillin and certain hydroxymethylpenicillanate 1,1-dioxides
EP0128718B1 (fr) Procédé d'obtention du 1,1-dioxyde de l'acide 6-(aminométhyl)-pénicillanique et dérivés de celui-ci
EP0002927B1 (fr) Dérivés de l'acide pénicillanique, procédés pour leur préparation et les compositions pharmaceutiques les contenant
CA1101841A (fr) Derives d'acides amino-spiro¬oxa (ou thia) cycloalcane-penam|-carboxyliques
CS227349B2 (cs) Způsob výroby 1,1-dioxopenicilanoyloxymethyl-6-(2-amino-2-fenylacetamido)- penicilanótů
CA1236827A (fr) Intermediaires monopenicillanoyl de carbonate d'hydroxymethyl
NO159659B (no) Fremgangsmaate for fremstilling av 1,1-dioksopenicillanoyloksymetyl-6-(2-amino-2-fenylacetamido)penicillanat-antibiotika.
GB1604755A (en) Penicillanic acid ester 1-oxides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19820322

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LU NL SE

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 16595

Country of ref document: AT

Date of ref document: 19851215

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3267505

Country of ref document: DE

Date of ref document: 19860102

ET Fr: translation filed
ITF It: translation for a ep patent filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
ITTA It: last paid annual fee
EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 82301296.8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20001221

Year of fee payment: 20

Ref country code: GB

Payment date: 20001221

Year of fee payment: 20

Ref country code: NL

Payment date: 20001221

Year of fee payment: 20

Ref country code: SE

Payment date: 20001221

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20010105

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20010110

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20010131

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20010212

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20010315

Year of fee payment: 20

BE20 Be: patent expired

Free format text: 20020315 *PFIZER INC.

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020314

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020314

Ref country code: LI

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020315

Ref country code: LU

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020315

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20020315

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020316

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Effective date: 20020314

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20020315

EUG Se: european patent has lapsed

Ref document number: 82301296.8